https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2017: results from the PAEDS-FluCAN Collaboration https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36948 Wed 19 Jan 2022 15:16:10 AEDT ]]> Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50856 Wed 09 Aug 2023 10:06:26 AEST ]]> Assessment and treatment of Hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19960 Sat 24 Mar 2018 07:58:34 AEDT ]]> Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18374 Sat 24 Mar 2018 07:52:39 AEDT ]]> Combination of vancomycin and β-lactam therapy for methicillin-resistant staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28522 Staphylococcus aureus (MRSA) bacteremia. Prospective clinical data are lacking. Methods: In this open-label, multicenter, clinical trial, adults with MRSA bacteremia received vancomycin 1.5 g intravenously twice daily and were randomly assigned (1:1) to receive intravenous flucloxacillin 2 g every 6 hours for 7 days (combination group) or no additional therapy (standard therapy group). Participants were stratified by hospital and randomized in permuted blocks of variable size. Randomization codes were kept in sealed, sequentially numbered, opaque envelopes. The primary outcome was the duration of MRSA bacteremia in days. Results: We randomly assigned 60 patients to receive vancomycin (n = 29), or vancomycin plus flucloxacillin (n = 31). The mean duration of bacteremia was 3.00 days in the standard therapy group and 1.94 days in the combination group. According to a negative binomial model, the mean time to resolution of bacteremia in the combination group was 65% (95% confidence interval, 41%-102%; P =. 06) that in the standard therapy group. There was no difference in the secondary end points of 28- and 90-day mortality, metastatic infection, nephrotoxicity, or hepatotoxicity. Conclusions: Combining an antistaphylococcal β-lactam with vancomycin may shorten the duration of MRSA bacteremia. Further trials with a larger sample size and objective clinically relevant end points are warranted. Australian New Zealand Clinical Trials Registry: ACTRN12610000940077 (www.anzctr.org.au).]]> Sat 24 Mar 2018 07:29:19 AEDT ]]> Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49510 Fri 19 May 2023 16:56:03 AEST ]]>